Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Merkel cell carcinoma, drawn from the whole corpus: 11 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Half of patients do not respond to PD-1 blockade and have no effective second line.
Immunosuppressed patients: high incidence, poor outcomes, contraindications to immunotherapy.
No validated adjuvant standard yet despite ADMEC-O.
Rarity limits trial size; registries (e.g. Seattle) carry much of the evidence.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 13 changes by month →When this page itself was last checked or edited.
Merkel cell carcinoma
Metastatic or recurrent locally advanced Merkel cell carcinoma
A milestone in how this cancer is treated.
Neoadjuvant nivolumab produced pathological complete responses in a substantial share of resectable Merkel cell carcinomas, with durable responses; nivolumab also showed activity in recurrent cervical cancer.
A milestone in how this cancer is treated.